← Eichor
Condition: Non Small Cell Lung Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Small Cell Lung Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Phase 1 · 1 location(s) · Dwight Owen · NCT06616623PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06977074A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · 9 location(s) · PAQ Therapeutics, Inc. · NCT07300150Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
Phase 1 · 2 location(s) · Ohio State University Comprehensive Cancer Center · NCT05136846Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decis
Phase N/A · 1 location(s) · Fudan University · NCT06684418Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Phase N/A · 2 location(s) · Gene Solutions · NCT06227728First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non
Phase 1/Phase 2 · 1 location(s) · Washington University School of Medicine · NCT07355205The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients
NA · 1 location(s) · Necmettin Erbakan University · NCT06428422A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06475300Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations
Phase 1/Phase 2 · 17 location(s) · Dizal (Jiangsu) Pharmaceutical Co., Ltd. · NCT07079475A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Phase 1 · 40 location(s) · Pfizer · NCT05355701A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 N
Phase 2/Phase 3 · 10 location(s) · Eikon Therapeutics · NCT07365319PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Phase 2 · 1 location(s) · Yongchang Zhang · NCT04144569Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Phase 2 · 1 location(s) · Guangdong Association of Clinical Trials · NCT06092086A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients
Phase 3 · 1 location(s) · Shanghai JMT-Bio Inc. · NCT06735391Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Manageme
Phase N/A · 4 location(s) · Peking University Cancer Hospital & Institute · NCT06926179Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After R
Phase N/A · 1 location(s) · Liaoning Cancer Hospital & Institute · NCT06109454Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment
NA · 2 location(s) · London Health Sciences Centre Research Institute OR Lawson R · NCT04852588Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects
Phase N/A · 3 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06800586Esomeprazole and Radiation Induced Esophagitis
Phase 2 · 1 location(s) · Rush University Medical Center · NCT06120803A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 · 62 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT05208762A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT043005563D Virtual Resection for Predicting Lung Function in VATS
Phase N/A · 1 location(s) · National Taiwan University Hospital · NCT07436598The Application Value of 68Ga-grazytracer PET in Immunotherapy for Stage III Non-small-cell Lung Cancer
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06623487An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06232265Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT06849167Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer
Phase N/A · 1 location(s) · Barzilai Medical Center · NCT06889467Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC
Phase 2 · 1 location(s) · Yang Hong · NCT07309952A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 5 location(s) · Avistone Biotechnology Co., Ltd. · NCT07538804The Associations of Sleep Disturbance With Therapy Efficacy and Prognosis of Lung Cancer
Phase N/A · 1 location(s) · Second Xiangya Hospital of Central South University · NCT06975384
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.